FOR IMMEDIATE RELEASE January 25th, 2015 For more information: Aaron Traywick Chief Operating Officer, GHPI 1.334.318.6151 atraywick@healthspanpolicy.org NEW THINKTANK TO PROMOTE RESEARCH, INNOVATION FOR TREATMENT OF UNDERLYING CAUSES OF AGING-RELATED…
Tony Wyss-Coray studies the impact of aging on the human body and brain. In this eye-opening talk, he shares new research from his Stanford lab and other teams which shows…
PROJECT M asked Jay Olshansky from the School of Public Health, University of Illinois, Chicago: What was THE medical breakthrough in modern history? Illustrations by Christoph Illigens.
Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism. Evidence from animal models and in vitro studies suggest that…
Researchers at the University of Washington in Seattle Healthy Aging and Longevity Research Institute have embarked on a new research regimen to determine the effects of potential drugs on optimizing…
Some exciting research from the University of Montreal has found that the drug metformin, commonly prescribed for diabetes and polycystic ovary syndrome (PCOS), has the potential to reduce multiple cancers…
“The Critical Need to Promote Research of Aging and Aging-related Diseases to Improve Health and Longevity of the Elderly Population” Aging and Disease, International Society on Aging and Disease (ISOAD),…
Areas of Policy Research and Development Key Priorities Connect our Fellows to the new $1.8 billion annual NIH fund for Cures currently under congressional approval through the 21st Century Act,…
Copyright (C) 2016 Global Healthspan Policy Institute
401 Ninth Street, NW, Suite 640, Washington DC 20004 (202) 674-7800
